Antiperistaltic Effect and Safety of L-menthol in the Elderly With Contraindication to Buscopan (Non-Buscopan)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04593836 |
Recruitment Status :
Recruiting
First Posted : October 20, 2020
Last Update Posted : October 20, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Upper Gastrointestinal Endoscopy | Drug: L-menthol Drug: Placebo | Phase 3 |
Endoscopy is a important tool for diagnosis and treatment of gastrointestinal diseases. Effective inhibition of gastrointestinal motility during examination is important to achieve good results and quality.
Traditionally, hyoscine-N-butylbromide (Buscopan) is the most commonly used drugs that inhibit intestinal peristalsis. But the side effects of drugs were mentioned in many studies, such as arrhythmia, increased glaucoma, dysuria in patients who have benign prostatic hypertrophy and allergic reactions, and may even cause anaphylactic shock. Peppermint oil is the extract of the natural plant (Mentha X piperita L) which was growth in North America and Europe. L-menthol is main component of peppermint oil. In animal experiments, peppermint oil had effect of calcium channel blockers and cause gastrointestinal smooth muscle relaxing effect. Clinically, peppermint oil preparations were used to relieve stress headache, non-ulcer dyspepsia and irritable bowel syndrome. The oral or intestinal local spraying of peppermint oil or L-menthol showed inhibition of intestinal peristalsis in many studies, and improved colonoscopy, barium enema, retrograde cholangiography , and upper gastrointestinal endoscopy examination.
With the aging of the population of Taiwan and the universality of endoscopy for elderly patients, the safety of endoscopy in elderly patients has more and more attention. According to ASGA guidelines, age is not a contraindication for endoscopy. But 50% of elderly patients have contraindications for hyoscine-N-butylbromide use. Therefore, effort to find alternative medicine to improve quality of endoscopy in elderly patients is necessary. Therefore, the investigators design a research for comparing effect and safety of L-menthol and placebo in elderly patients who have contraindication of hyoscine-N-butylbromide.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Supportive Care |
Official Title: | Antiperistaltic Effect and Safety of L-menthol and Placebo for Upper GI Endoscopy in the Elderly With Contraindication to Buscopan: a Prospective, Randomized, Double-blind Study |
Actual Study Start Date : | March 2012 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | December 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
|
Drug: L-menthol
20ml 0.8% L-menthol spray on the pyloric ring and observe the gastric peristalsis
Other Name: Peppermint oil |
Placebo Comparator: Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
|
Drug: Placebo
20ml 0.8% placebo spray on the pyloric ring and observe the gastric peristalsis
Other Name: Olive oil |
- Peristaltic grade [ Time Frame: 10 mins ]Grade 1: no peristalsis; grade 2: mild peristalsis; grade 3: moderate peristalsis; grade 4: vigorous peristalsis; grade 5: markedly vigorous peristalsis.
- Pylorus contraction ratio [ Time Frame: 3 mins ]Contraction ratio (%)= [(maximal pyloric ring diameter - minimal pyloric ring diameter)/minimal pyloric ring diameter] x 100
- Pylorus opening ratio: maximum and minimum [ Time Frame: 3 mins ]Opening ratio (%) = [(pyloric ring diameter after administration of the antispasmodic agent - pyloric ring diameter before administration of the antispasmodic agent) / pyloric ring diameter before administration of the antispasmodic agent] x 100
- Adverse effect of patients [ Time Frame: 48 hours ]record all adverse effect after study, include abdominal pain, heart burn, headache, allergy, etc.
- VAS score of patient about procedure [ Time Frame: 10 mins ]VAS score 1-10 about the painful sensation of patient during procedure
- Satisfaction of endoscopist [ Time Frame: 10 mins ]Four score was evaluated: very easy, easy, slightly difficult and difficult about the procedure due to gastric spasm

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 65 Years and older (Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- >65 years old
- routine endoscopic examination
- Contraindication to Buscopan(such as arrhythmia, glaucoma, benign prostatic hyperplasia, ischemic heart disease...)
Exclusion Criteria:
- Status post gastric or duodenal surgery
- The patient with critical illness are not suitable for the endoscopic examination
- Upper gastrointestinal bleeding
- Gastric tumor
- Gastric or duodenal ulcers are larger than 2 cm
- Severe pyloric obstruction or deformity
- Cancer patients received chemotherapy or radiation therapy
- Had peppermint allergy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04593836
Contact: Ming-Chih Hou, MD | 886-2-28712121 ext 1320 | mchou@vghtpe.gov.tw |
Taiwan | |
Taipei Veterans General Hospital | Recruiting |
Taipei, Taiwan, 11217 | |
Contact: Ming-Chih Hou, MD 886-2-28712121 ext 1320 mchou@vghtpe.gov.tw | |
Contact: Han-Chieh Lin, MD 886-2-28712121 ext 7506 hclin@vghtpe.gov.tw | |
Principal Investigator: Ming-Chih Hou, MD |
Principal Investigator: | Ming-Chih Hou, MD | Taipei Veterans General Hospital, Taiwan |
Responsible Party: | Taipei Veterans General Hospital, Taiwan |
ClinicalTrials.gov Identifier: | NCT04593836 |
Other Study ID Numbers: |
V101A-002 |
First Posted: | October 20, 2020 Key Record Dates |
Last Update Posted: | October 20, 2020 |
Last Verified: | October 2020 |
Upper gastrointestinal endoscopy Peppermint oil L-menthol Elderly |
Peppermint oil Menthol Antipruritics Dermatologic Agents Antiemetics |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Gastrointestinal Agents Parasympatholytics |